Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Nektar Therapeutics/ 144

Notice of Proposed Sale · 144

Nektar Therapeutics

NKTRNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 18, 2026Accepted Aug 18, 2026, 3:57 PM EDTCIK 906709Accession 0001959173-26-006172
View company →Permanent SEC source ↗
Share

Company context

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory Tcell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Current securities

NKTRNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureOct 1, 2026
  2. Other EventsSep 25, 2026
  3. Regulation FD DisclosureSep 8, 2026
  4. 144 filingAug 18, 2026
  5. SCHEDULE 13G/A - filed by Two Seas Capital LP regarding NEKTAR THERAPEUTICSAug 14, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.